Patent: 5,545,405

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,545,405

Title:	Method for treating a mammal suffering from cancer with a cho-glycosylated antibody
Abstract:	The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
Inventor(s):	Page; Martin J. (Beckenham, GB)
Assignee:	Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:	08/335,401
Patent Claims:	see list of patent claims

Details for Patent 5,545,405

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genzyme	LEMTRADA	alemtuzumab	INJECTABLE;INJECTION	103948	003	2001-05-07	Start Trial	Burroughs Wellcome Co. (Research Triangle Park, NC)	2013-08-13	RX	Orphan	company
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	002	2001-05-07	Start Trial	Burroughs Wellcome Co. (Research Triangle Park, NC)	2013-08-13	RX	Orphan	company
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	001	2001-05-07	Start Trial	Burroughs Wellcome Co. (Research Triangle Park, NC)	2013-08-13	RX	Orphan	company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 5,545,405

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	9108248	Start Trial
United States of America	2002182208	Start Trial
United States of America	2003035799	Start Trial
United States of America	2004228857	Start Trial
United States of America	2008279852	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.